Skip to content
DataLookout
Menu

NCT07933536

A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis

StatusNot Yet Recruiting
PhasePhase 2
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percentage of Participants Achieving at least a 90% reduction from Baseline in Psoriasis Area and Severity Index (PASI 90)
Timeframe: Week 28
Number of Participants with Adverse Events (AEs)
Timeframe: Up to 72 Weeks

Secondary (3)

Percentage of Participants Achieving 100% Reduction from Baseline in PASI 100
Percentage of Participants Achieving ≥10% Body Weight Reduction from Baseline
Percent Change from Baseline in Body Weight

Arms and interventions

Risankizumab and ABBV-295 Combination TherapyExperimental

Participants will receive risankizumab in combinations with ABBV-295 for up to 52 weeks.

Risankizumab and ABBV-295 Matching PlaceboActive comparator

Participants will receive risankizumab with ABBV-295 matching placebo for up to 52 weeks.

Drugs: Risankizumab, ABBV-295, ABBV-295 Placebo